Details for New Drug Application (NDA): 050646
✉ Email this page to a colleague
NDA 050646 describes CEPTAZ, which is a drug marketed by Glaxosmithkline and is included in one NDA. Additional details are available on the CEPTAZ profile page.
The generic ingredient in CEPTAZ is ceftazidime. There are seventeen drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the ceftazidime profile page.
The generic ingredient in CEPTAZ is ceftazidime. There are seventeen drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the ceftazidime profile page.
Summary for 050646
| Tradename: | CEPTAZ |
| Applicant: | Glaxosmithkline |
| Ingredient: | ceftazidime |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 050646
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | 500MG/VIAL | ||||
| Approval Date: | Sep 27, 1990 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | 1GM/VIAL | ||||
| Approval Date: | Sep 27, 1990 | TE: | RLD: | No | |||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | 2GM/VIAL | ||||
| Approval Date: | Sep 27, 1990 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
